Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Decibel Therapeutics, Inc.

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Tickers DBTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.